Adam D. Cohen, MD, overviews phase 1 findings for cevostamab and outlines future research directions for the agent in relapsed/refractory multiple myeloma.
News|Videos|November 10, 2025
Rezatapopt For Locally Advanced or Metastatic Solid Tumors With a TP53 Y220C Mutation: Initial Analysis of the Pivotal PYNNACLE Phase 2 Trial
Author(s)Alison Schram, MD
Alison M. Schram, MD, of Memorial Sloan Kettering Cancer Center, discusses initial results from the pivotal Phase 2 PYNNACLE trial evaluating rezatapopt, a first-in-class p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation.
Advertisement
Advertisement
Related to this article
New insights on early detection, cancer biology and surgical innovation in head and neck cancer highlighted at international research meeting.
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
A rituximab biosimilar has been approved by the FDA.
Camrelizumab Plus Nab-Paclitaxel Yields Efficacy in Previously Treated Advanced Urothelial Carcinoma
Later-line camrelizumab plus nab-paclitaxel produced durable responses in platinum-treated advanced urothelial carcinoma.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
Prithviraj Bose, MD, overviews the ongoing investigation of sapablursen in polycythemia vera.
Continuing maintenance therapy with lenalidomide beyond 2 years after initial treatment did not improve overall survival in standard-risk myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to Olomorasib in KRAS G12C+ Pancreatic Cancer
2
FDA Grants Orphan Drug Designation to Zocilurtatug Pelitecan for Neuroendocrine Carcinomas
3
Sapablursen Represents Potential Avenue for Improved Hepcidin Production in Polycythemia Vera
4
OS Wins, New Approvals, and Practice-Changing Data: Breaking Down the Biggest NSCLC News From ASCO 2026
5